Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

bapotulimab

A mouse/human cross-reactive immunoglobulin G2 (IgG2) monoclonal antibody against the immune checkpoint immunoglobulin-like domain containing receptor 2 (ILDR2; Chromosome 1 Open Reading Frame 32; C1orf32), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bapotulimab targets, binds to and inhibits ILDR2, thereby blocking the immunosuppressive activity of ILDR2. This prevents ILDR2-mediated inhibition of T-cell activities and induces a cytotoxic T-lymphocyte (CTL) response against tumor cells. ILDR2, a type I transmembrane protein belonging to the B7 family of immunomodulatory receptors, negatively regulates T-cell responses.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-ILDR2 inhibitor BAY1905254
anti-ILDR2 monoclonal antibody BAY 1905254
anti-immunoglobulin-like domain containing receptor 2 MoAb BAY1905254
ILDR2 function-blocking antibody BAY1905254
immune checkpoint inhibitor BAY1905254
Code name:BAY 1905254
BAY-1905254
BAY1905254
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search